Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Prostate Cancer
Prostate Cancer
,
Conference Highlights ASCO
¹⁷⁷Lu-PSMA-617 Prolongs Survival in Patients with Metastatic Castration-Resistant Prostate Cancer
Phoebe Starr
Phoebe Starr
Read More
Prostate Cancer
¹⁷⁷Lu-PSMA-617 Superior to Cabazitaxel in Metastatic Prostate Cancer
Phoebe Starr
Phoebe Starr
Read More
Prostate Cancer
Cabozantinib plus Atezolizumab Combination Shows Meaningful Activity in Metastatic Prostate Cancer
Phoebe Starr
Phoebe Starr
Read More
Prostate Cancer
Oral Relugolix Equals Standard ADT, Slashes Cardiac Events in Patients with Advanced Prostate Cancer
Phoebe Starr
Phoebe Starr
Read More
Prostate Cancer
Early Phase 2 Data Promising for Lutetium-177 PSMA-617 in Metastatic Prostate Cancer
Phoebe Starr
Phoebe Starr
Read More
FDA Approvals
,
Prostate Cancer
,
Select Drug Profiles
Lynparza First Targeted Therapy Approved for Metastatic Prostate Cancer with HRR Mutation
Read More
Drug Updates
,
FDA Approvals
,
Prostate Cancer
Xtandi Now Approved for Metastatic Castration-Sensitive Prostate Cancer
Read More
Prostate Cancer
Enzalutamide or Apalutamide Added to ADT Improves Outcomes in Hormone-Sensitive Prostate Cancer
Phoebe Starr
Phoebe Starr
Read More
Prostate Cancer
With Access to Care, Black Men in the United States Have Same Prostate Cancer Outcomes as White Men
Phoebe Starr
Read More
Prostate Cancer
Abiraterone a Game-Changer in the Frontline Treatment of Metastatic Prostate Cancer
Wayne Kuznar
Read More
1
2
3
Page 1 of 3
Results 1 - 10 of 26